Metabolic & Cardiometabolic
statins decreases major adverse cardiovascular events (secondary prevention)
In plain terms: Do statins reduce major cardiovascular events in patients with established cardiovascular disease?
Part of: 💊 statins
Yes — among the best-supported claims in cardiology: large RCTs and CTT meta-analyses show a consistent ~20-25% relative risk reduction in major vascular events per ~1 mmol/L LDL lowering.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (9)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kritharides 2015 · Future Cardiol | meta-analysis | supports | high | CTT meta-analysis of 27 trials/174,000 participants: statins cut major vascular events ~21% per mmol/L LDL reduction in men and women. |
| CTT Collaboration 2010 · Lancet | meta-analysis | supports | high | 170,000 participants, 26 trials: further LDL lowering cut major vascular events ~22% per mmol/L; more-intensive vs less-intensive added benefit, no excess non-vascular mortality. |
| LIPID Study Group 1998 · N Engl J Med | RCT | supports | high | LIPID: pravastatin in 9,014 CHD patients lowered coronary death 24% and total mortality 22% across a broad range of baseline cholesterol. |
| Burger 2024 · Atherosclerosis | meta-analysis | supports | high | Meta-analysis of 60 RCTs found LDL-lowering therapy consistently reduces cardiovascular risk, with benefit growing over treatment time. |
| Cholesterol Treatment Trialists 2005 · Lancet | meta-analysis | supports | high | Meta-analysis of 90,056 patients in 14 trials: ~21% reduction in major vascular events per 1 mmol/L LDL reduction; benefit largely independent of baseline lipids. |
| Scandinavian Simvastatin Survival Study 1994 · Lancet | RCT | supports | high | 4S: simvastatin in 4,444 CHD patients cut all-cause mortality 30% (RR 0.70) and major coronary events 34% over 5.4 years — landmark secondary-prevention trial. |
| Kostapanos 2011 · World J Cardiol | RCT | supports | moderate | Review of JUPITER RCT confirms rosuvastatin significantly reduced major cardiovascular events versus placebo. |
| Heart Protection Study 2002 · Lancet | RCT | supports | high | HPS: simvastatin in 20,536 high-risk individuals cut major vascular events ~24% regardless of baseline LDL, age, sex, or diabetes status. |
| Cannon PROVE-IT TIMI 22 2004 · N Engl J Med | RCT | supports | high | PROVE-IT: after acute coronary syndrome, intensive atorvastatin 80mg beat moderate pravastatin, lowering death/major CV events 16% — supports lower-is-better in secondary prevention. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.